Quarterly ResultMay 13, 2026, 04:14 PM
Talphera Q1 Net Loss $2.6M; NEPHRO CRRT Study Progresses
AI Summary
Talphera, Inc. announced its first quarter 2026 financial results, reporting a net loss of $2.6 million, consistent with the prior year's quarter. The company also provided a corporate update, highlighting significant progress in its NEPHRO CRRT clinical study for nafamostat, which has exceeded 50% enrollment and is anticipated to conclude later this year. As of March 31, 2026, Talphera held $21.1 million in cash and investments.
Key Highlights
- Net loss attributable to common shareholders was $2.6 million for Q1 2026, flat compared to Q1 2025.
- Basic and diluted loss per share was $0.04 for Q1 2026, down from $0.10 in Q1 2025.
- Cash and investments balance was $21.1 million as of March 31, 2026.
- Combined R&D and SG&A expenses totaled $3.9 million for Q1 2026, up from $2.9 million in Q1 2025.
- NEPHRO CRRT study reached 50% enrollment (35 patients) in March 2026, with completion expected in 2026.
- Closed $4.1 million third tranche of the March 2025 private placement financing.